Eligo Bioscience is a biotechnology company focused on the development of innovative microbiome therapies. The company leverages cutting-edge technology to engineer beneficial microbes that can specifically target and eliminate harmful bacteria, aiming to treat a range of diseases linked to the human microbiome.

Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing.

AGORANOV

Worldwide Innovation Challenge

European Commission

CARB-X

EASME - EU Executive Agency for SMEs

Seventure Partners

Khosla Ventures

Bpifrance

Sanofi Ventures

Eligo Bioscience

Exciting times at Eligo! Following our Series B announcement, we're gearing up to take the first-ever topical CRISPR therapy to the clinic. 
If you're eager to have a meaningful impact on the lives of millions of patients, we would love to hear from you. 
We are indeed on the lookout for passionate and driven individuals to join our Development, Finance, Synthetic Biology & Bioinformatics teams.

https://eligo.bio/careers/

🎉 News alert: We are thrilled to announce that we have just closed a $30 million financing round led by Sanofi Ventures, with the participation of Bpifrance (Innobio2), and our existing investors Khosla Ventures and Seventure Partners.

 🧬 This funding will enable us to advance and test in the clinic our CRISPR-based medicine for the 90M+ patients suffering from moderate-to-severe acne vulgaris. It will also help us to further develop our proprietary platform to address other immuno-inflammatory diseases, cancers, and infectious diseases.

 🚀 This is a defining moment for Eligo as this funding places us in a strong position to make a significant leap in treating diseases by editing the genetic makeup of the human microbiome.

#CRISPR #SyntheticBiology #GeneEditing #Microbiome #Acnetreatment 

https://lnkd.in/ejTC-DXS

BIO:ELIGO

Eligo Bioscience

Analysis Not Available